Report of Foreign Issuer (6-k)

Date : 09/17/2019 @ 2:20PM
Source : Edgar (US Regulatory)
Stock : Medicure Inc. (PC) (MCUJF)
Quote : 3.58  -0.11 (-2.98%) @ 9:01PM

Report of Foreign Issuer (6-k)








Washington, D.C. 20549







For the month of September 2019


Commission File Number: 001-31995



(Translation of registrant's name into English)


2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.


Form 20-F x Form 40-F o


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o


Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.


Yes o No x


If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.








Exhibit Title
99.1 News Release Dated September 17, 2019 - Medicure Announces Launch of New and Improved ReDS™ PRO











Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


  Medicure Inc.
Date: September 17, 2019 By: /s/ Dr. Albert D. Friesen                           
  Dr. Albert D. Friesen
  Title: President & CEO



Exhibit 99.1


Medicure Announces Launch of New and Improved ReDS™ PRO

WINNIPEG, Sept. 17, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the launch of the ReDSTM PRO ("ReDSTM PRO") system, the next generation of lung fluid management technology for heart failure. The debut of the new system took place at the recent Heart Failure Society of America ("HFSA") conference in Philadelphia, PA. ReDSTM PRO is optimized for the point-of-care market, designed for use in hospitals and sub-acute facilities. ReDSTM PRO utilizes non-invasive low energy radio frequency technology that produces reliable fluid volume readings after only 45 seconds of measurement. The ReDSTM PRO can be utilized across the continuum of hospital care, from the emergency department to discharge and subacute rehabilitation.

Medicure previously announced, on January 28, 2019, that it had entered an agreement with Sensible Medical Innovations Inc. ("Sensible") to become the exclusive marketing partner for the ReDS™ point of care system in the United States, a non-invasive, FDA-cleared medical device that provides an accurate, actionable and absolute measurement of lung fluid which is important in the management of congestive heart failure.  The ReDSTM PRO represents the next generation of this device.

"Medicure was excited to introduce the ReDSTM PRO at the HFSA conference in an effort to improve the quality of life of heart failure patients. The device is being sold by Medicure directly to hospitals through our existing commercial operation and supports our mission of being a significant, value-based, cardiovascular company focused on the U.S. market." commented Dr. Albert Friesen, Chief Executive Officer for Medicure.

Medicure continues to hold a 7.71% equity stake, on a fully diluted basis, in Sensible.

About ReDSTM PRO System

The ReDSTM PRO is an accurate measurement tool to evaluate pulmonary congestion providing additional information to assist a physician in their assessment of a patient's condition. Assessment with the aid of ReDSTM technology has helped physicians at facilities across the country to better manage their patients' heart failure, with the goal of avoiding readmissions. For more information please visit

About Medicure

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit

About Sensible

Sensible is a market leader in medical radar monitoring and imaging technology. ReDS™ was adapted for medical use from military 'see-through-wall' technology. The technology is well-positioned to be a difference maker in a wide range of applications and to become the next-generation lung fluid monitoring modality. 

To be added to Medicure's e-mail list, please visit:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content:

SOURCE Medicure Inc.


View original content:

%CIK: 0001133519

For further information: James Kinley, Chief Financial Officer, Tel. 888-435-2220, Fax 204-488-9823, E-mail:,

CO: Medicure Inc.

CNW 09:59e 17-SEP-19


This regulatory filing also includes additional resources:

Medicure Inc. (PC) (USOTC:MCUJF)
Historical Stock Chart

1 Year : From Dec 2018 to Dec 2019

Click Here for more Medicure Inc. (PC) Charts.

Medicure Inc. (PC) (USOTC:MCUJF)
Intraday Stock Chart

Today : Sunday 15 December 2019

Click Here for more Medicure Inc. (PC) Charts.

Latest MCUJF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.